Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(8)

MIXED(4)

RADIATION(1)

Nivolumab

1 trial

phase_1_2

hackensack-meridian-health

Mycophenolate mofetil (MMF)

1 trial

phase_2

hackensack-meridian-health

Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)

1 trial

phase_3

hackensack-meridian-health

Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)

1 trial

phase_3

hackensack-meridian-health

Cyclophosphamide and Sirolimus

1 trial

phase_1_2

hackensack-meridian-health

Low dose IL-2, Vidaza, Cytoxan & Sirolimus

1 trial

phase_1_2

hackensack-meridian-health

Post-transplant Cyclophosphamide (PTCy)

1 trial

phase_2

hackensack-meridian-health

Tacrolimus

1 trial

phase_2

hackensack-meridian-health

+5 more interventions

13 unique interventions3 categories

Analytics

Trial Phases

Phase 12

Phase 23

Phase 31

Trial Status

Recruiting1

Terminated3

Role Distribution

Principal Investigator4

PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT07214688Phase 2Recruiting

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Allogeneic Stem Cell Transplant Recipient

PrincipalinvestigatorStart date: 2026-01-06

NCT02681302Phase 1/2Terminated

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

LymphomaMultiple Myeloma

PrincipalinvestigatorStart date: 2016-06-07

NCT01366612Phase 3Terminated

Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

Acute Myelogenous LeukemiaChronic Myelogenous LeukemiaMyelodysplastic Syndrome+2 more

PrincipalinvestigatorStart date: 2010-06-16

NCT01453140Phase 1/2Terminated

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Graft Versus Host Disease

Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Leukemia, Myeloid, Acute1 Allogeneic Stem Cell Transplant Recipient1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive1 Graft vs Host Disease1 Lymphoma1 Multiple Myeloma1 Myelodysplastic Syndromes1 Myeloid Malignancies1

Affiliations

Hackensack Meridian Health

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

24 trials

Shared therapeutic areas:

Multiple MyelomaLymphomaLeukemia, Myelogenous, Chronic, BCR-ABL Positive+4 more

Similarity Score23%

Arnon Nagler, MD

Chaim Sheba Medical Center

12 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL Positive+3 more

Similarity Score20%

Yves Beguin, MD, PhD

CHU-ULg

7 trials

Shared therapeutic areas:

Graft vs Host DiseaseLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Acute+3 more

Similarity Score20%

Areej El-Jawahri, MD

Massachusetts General Hospital

21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteGraft vs Host DiseaseLymphoma+2 more

Similarity Score17%

Jorge Cortes, MD

M.D. Anderson Cancer Center

24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyelodysplastic Syndromes+2 more

Similarity Score17%

Qifa Liu

Nanfang Hospital, Southern Medical University

33 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesLeukemia, Myelogenous, Chronic, BCR-ABL Positive+1 more

Similarity Score13%

David Avigan, MD

Beth Israel Deaconess Medical Center

17 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL Positive+1 more

Similarity Score13%

Guillermo Garcia-Manero, MD

M.D. Anderson Cancer Center

18 trials

Shared therapeutic areas:

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteMyeloproliferative Disorders

Similarity Score10%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

19 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLymphoma

Similarity Score7%

Courtney DiNardo, MD

M.D. Anderson Cancer Center

16 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteMyelodysplastic Syndromes

Similarity Score7%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT07214688Phase 2PrincipalInvestigator

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Allogeneic Stem Cell Transplant Recipient

Recruiting

NCT02681302Phase 1/2PrincipalInvestigator

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

LymphomaMultiple Myeloma

Terminated

NCT01366612Phase 3PrincipalInvestigator

Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

Acute Myelogenous LeukemiaChronic Myelogenous LeukemiaMyelodysplastic Syndrome+2 more

Terminated

NCT01453140Phase 1/2PrincipalInvestigator

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Graft Versus Host Disease

Terminated

All 4 trials loaded